Report Overview

The South Korea prostate cancer therapeutics market size stood at around USD xx billion in 2020 and is projected to reach xx billion by 2028, exhibiting a CAGR of around xx% during the forecast period.

Prostate cancer is the second most common cancer in men worldwide, and in South Korea it has 7th highest incidence rate of all cancer sites. Although there is a tendency to recognize that prostate cancer as a mild cancer, special attention is required due to the high rate of progression and malignancy of prostate cancer occurring in Korea compared to Western prostate cancer. Early detection and aggressive treatment have improved the overall survival rate of prostate cancer, but some of them lead to metastatic prostate cancer.

 



Market Drivers

In Korea, the incidence of prostate cancer has increased significantly due to the westernization of diet and the aging of the population. The incidence of prostate cancer increased by 32% in 10 years from 52 per 100,000 in 2006 to 68.6 in 2015. The number of prostate cancer patients reported in Korea in 2020 were 13,873. The 5-year prevalence rate was reported to be 162.45 per 100,000 in GLOBOCAN report for year 2020. Incessantly increasing burden of the disease is a primary factor propelling the market drive.

The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.